Hong Kong IPO delivers $421M to Innovent — fourth listed biotech in six months

Say what you may about the biotech chapter of the Hong Kong Stock Exchange, but it has not stopped Innovent Biologics from reaping $421 million in its public debut — the largest of the three maiden IPOs so far.